Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. blms 4 tb

BLMs 4 TB SIGNED

Beta-lactams for Tuberculosis Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BLMs 4 TB project word cloud

Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.

infections    last    arose    point    trials    generation    resistance    prospects    months    discontinued    urgently    treat    50    pk    glaxosmithkline    leads    ram    extensively    therapies    validated    dim    severe    optimal    deadly    regarded    beneficiary    disease    life    pharmacokinetic    strains    barros    data    positive    dr    transcriptomic    clinical    led    unclear    family    gsk    infectious    combo    administration    prevent    iia    longer    outcomes    drug    takes    market    pharmacodynamics    cephems    modeling    oacute    cephalosporins    linked    record    patients    meropenem    infected    lactams    blms    poor    specificities    xdr    quality    microscopy    trial    adherence    dosage    blm    carbapenems    killing    bacterial    hope    decades    treatment    renewed    time    mdr    subset    pd    head    24    track    treatments    mathematical    tuberculosis    agents    therapy    anti    questions    inform    undergo    relapse    shorten    never    frequency    techniques    first    worldwide    carbapenem    antibiotics    proteomic    pursued    garc    safest    ineffective    unpleasant    microbiology    report    molecular    lapse    outcome    virtually    tb    beta    resistant    answer    iacute   

Project "BLMs 4 TB" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO 

Organization address
address: PASEO MARIA AGUSTIN 36 EDIFICIO PIGNATELLI PTA 30 PL 2
city: ZARAGOZA
postcode: 50004
website: www.araid.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO ES (ZARAGOZA) coordinator 170˙121.00

Map

 Project objective

Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.

Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.

Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.

To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More  

LieLowerBounds (2019)

Lower bounds for partial differential operators on compact Lie groups

Read More  

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More